How BNCT will improve outcomes for the most difficult-to-treat cancers

Dramatic advances in cancer treatment have completely transformed the landscape of cancer care in the last several decades.

TAE Life Sciences is developing a next-generation boron neutron capture therapy for cancer. After recently introducing Alphabeam, a compact and affordable accelerator-based neutron system suitable for hospital settings, the company is now focusing on the development of novel boron drugs with improved tumor selectivity and increased 10B loads.